Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01202188
Registration number
NCT01202188
Ethics application status
Date submitted
13/09/2010
Date registered
15/09/2010
Date last updated
9/09/2013
Titles & IDs
Public title
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Query!
Scientific title
A 26-week Treatment Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled (Open Label) Study to Assess the Efficacy, Safety and Tolerability of QVA149 (110/50 µg q.d.) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Query!
Secondary ID [1]
0
0
2009-017772-25
Query!
Secondary ID [2]
0
0
CQVA149A2303
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SHINE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease (COPD)
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - indacaterol and glycopyrronium (QVA149)
Treatment: Drugs - glycopyrronium (NVA237)
Treatment: Drugs - indacaterol (QAB149)
Treatment: Drugs - tiotropium
Treatment: Drugs - placebo
Experimental: indacaterol and glycopyrronium (QVA149) - QVA149 110/50 µg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
Active Comparator: glycopyrronium (NVA237) - NVA237 50 µg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
Active Comparator: indacaterol (QAB149) - QAB149 150 µg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
Active Comparator: tiotropium - Tiotropium 18 µg capsules for inhalation delivered once daily via HandiHaler® device for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
Placebo Comparator: Placebo - Matching placebo capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
Treatment: Drugs: indacaterol and glycopyrronium (QVA149)
Capsules for inhalation delivered via SDDPI.
Treatment: Drugs: glycopyrronium (NVA237)
Capsules for inhalation delivered via SDDPI.
Treatment: Drugs: indacaterol (QAB149)
Capsules for inhalation delivered via SDDPI.
Treatment: Drugs: tiotropium
Capsules for inhalation delivered via HandiHaler® device.
Treatment: Drugs: placebo
Placebo to match capsules for inhalation delivered via SDDPI.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Trough Forced Expiratory Volume In One Second (FEV1) After 26 Weeks of Treatment
Query!
Assessment method [1]
0
0
Spirometry was performed according to internationally accepted standards. Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values. A mixed model was used with treatment as a fixed effect with baseline FEV1 and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [1]
0
0
23 hours 15 minutes and 23 hour 45 minute post-dose Week 26
Query!
Secondary outcome [1]
0
0
Transitional Dyspnea Index (TDI) Focal Score at Week 26
Query!
Assessment method [1]
0
0
A trained assessor interviewed the patient and graded the degree of impairment due to dyspnea (difficulty breathing). TDI focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort. Each domain is scored from -3 (major deterioration) to 3 (major improvement) to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score. A mixed model was used with treatment as a fixed effect with Baseline Dyspnea Index Score and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [1]
0
0
Week 26
Query!
Secondary outcome [2]
0
0
St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 26
Query!
Assessment method [2]
0
0
SGRQ is a health related quality of life questionnaire consisting of 51 items in three areas: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). The total score is 0 to 100 with a higher score indicating poorer health status. A mixed model was used with treatment as a fixed effect with Baseline SGRQ and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [2]
0
0
26 weeks
Query!
Secondary outcome [3]
0
0
Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Over 26 Weeks
Query!
Assessment method [3]
0
0
The number of puffs of rescue medication taken in the previous 12 hours was record in patient diary in the morning and in the evening for 26 weeks. The total number of puffs per day was calculated and divided by the number of days with data to determine the mean daily number of puffs of rescue medication for each patient. Rescue medication data recorded during the 14 day run-in was used to calculate the baseline. A negative change from baseline indicates improvement. A mixed model was used with treatment as a fixed effect with baseline number of puffs and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [3]
0
0
Baseline, Week 26
Query!
Secondary outcome [4]
0
0
Trough Forced Expiratory Volume In One Second (FEV1) After 26 Weeks of Treatment With QVA149, QAB149 and NVA237 Compared to Placebo
Query!
Assessment method [4]
0
0
Spirometry was performed according to internationally accepted standards. Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values. A mixed model was used with treatment as a fixed effect with baseline FEV1 and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [4]
0
0
23 hours 15 minutes and 23 hour 45 minute post-dose Week 26
Query!
Secondary outcome [5]
0
0
Trough Forced Expiratory Volume In One Second (FEV1) After 26 Weeks of Treatment With QVA149 Compared to Tiotropium
Query!
Assessment method [5]
0
0
Spirometry was performed according to internationally accepted standards. Trough FEV1 was defined as the mean of the 23 hour 15 minute and 23 hour 45 minute post-dose values. A mixed model was used with treatment as a fixed effect with baseline FEV1 and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [5]
0
0
23 hours 15 minutes and 23 hour 45 minute post-dose Week 26
Query!
Secondary outcome [6]
0
0
Baseline Transitional Dyspnea Index (BDI/TDI) Focal Score at Week 12 and Week 26
Query!
Assessment method [6]
0
0
A trained assessor interviewed the patient and graded the degree of impairment due to dyspnea (difficulty breathing). BDI/TDI focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score.
A mixed model was used with treatment as a fixed effect with Baseline Dyspnea Index Score and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators as covariates and included baseline smoking status, baseline inhaled corticosteroids and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [6]
0
0
Baseline, Week 12, Week 26
Query!
Secondary outcome [7]
0
0
Percentage of Patients With a Clinically Important Improvement of at Least 1 Point in TDI Focal Score After 26 Weeks of Treatment
Query!
Assessment method [7]
0
0
A trained assessor interviewed the patient and graded the degree of impairment due to dyspnea (difficulty breathing) at Week 12 and Week 26. TDI focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort. The BDI (baseline) was measured at Day 1. The TDI captures changes from baseline. Each domain is scored from -3 (major deterioration) to 3 (major improvement) to give an overall TDI focal score of -9 to 9.
Query!
Timepoint [7]
0
0
Baseline, Week 26
Query!
Secondary outcome [8]
0
0
St. George's Respiratory Questionnaire (SGRQ) Total Score After 12 and 26 Weeks of Treatment
Query!
Assessment method [8]
0
0
SGRQ is a health related quality of life questionnaire consisting of 51 items in three areas: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). The total score is 0 to 100 with a higher score indicating poorer health status. A mixed model was used with treatment as a fixed effect with Baseline SGRQ and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [8]
0
0
Week 12, Week 26
Query!
Secondary outcome [9]
0
0
Percentage of Patients With a Clinically Important Improvement From Baseline of at Least 4 Units in the SGRQ Total Score After 26 Weeks of Treatment
Query!
Assessment method [9]
0
0
SGRQ is a health related quality of life questionnaire consisting of 51 items in three areas: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). The total score is 0 to 100 with a higher score indicating poorer health status.
Query!
Timepoint [9]
0
0
Baseline, Week 26
Query!
Secondary outcome [10]
0
0
Percentage of Nights With "No Night Time Awakenings" Over 26 Weeks
Query!
Assessment method [10]
0
0
A day with no night time awakenings is defined from the diary data as any day where the patient did not wake up due to COPD symptoms. The percentage of nights is calculated by the number of days with no nighttime awakenings/total number of days with evaluable data X 100. A mixed model was used with treatment as a fixed effect with baseline Percent days and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [10]
0
0
26 Weeks
Query!
Secondary outcome [11]
0
0
Percentage of Days With "No Daytime Symptoms" Over 26 Weeks
Query!
Assessment method [11]
0
0
A day with no day time symptoms is defined from the diary data as any day where the patient recorded no coughing, no wheezing, no sputum production and no breathlessness during the previous 12 hours (approximately 8AM to 8PM). The percentage of days is calculated by the number of days with no daytime symptoms/total number of days with evaluable data X 100. A mixed model was used with treatment as a fixed effect with baseline Percent of days and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [11]
0
0
26 Weeks
Query!
Secondary outcome [12]
0
0
Percentage of "Days Able to Perform Usual Daily Activities" Over 26 Weeks
Query!
Assessment method [12]
0
0
Patients answered the question "Did your respiratory symptoms stop you performing your usual activities today?-Not at all in their daily diary. The percentage of days is calculated by the number of days patient is able to perform daily activities/total number of days with evaluable data X 100. A mixed model was used with treatment as a fixed effect with baseline Percent of Days and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [12]
0
0
26 Weeks
Query!
Secondary outcome [13]
0
0
Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication at Week 12 and Week 26
Query!
Assessment method [13]
0
0
The number of puffs of rescue medication taken in the previous 12 hours was record in patient diary in the morning and in the evening for 26 weeks. The total number of puffs per day was calculated and divided by the number of days with data to determine the mean daily number of puffs of rescue medication for each patient. Rescue medication data recorded during the 14 day run-in was used to calculate the baseline. A negative change from baseline indicates improvement. A mixed model was used with treatment as a fixed effect with baseline number of puffs and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [13]
0
0
Baseline, Week 12, Week 26
Query!
Secondary outcome [14]
0
0
Change From Baseline (BL) in the Daytime and Night Time Rescue Medication Use (Number of Puffs) Over 26 Weeks
Query!
Assessment method [14]
0
0
The number of puffs of rescue medication taken in the previous 12 hours was record in patient diary in the morning and in the evening for 26 weeks. The total number of puffs in the morning and evening were calculated and divided by the number of days with data to determine the mean daily number of daytime and nighttime puffs. A mixed model was used with treatment as a fixed effect with baseline number of puffs and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline (BL) ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [14]
0
0
Baseline, Week 26
Query!
Secondary outcome [15]
0
0
Percentage of "Days With no Rescue Medication Use" Over 26 Weeks
Query!
Assessment method [15]
0
0
A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours. The percentage of days is calculated by the number of days with no rescue medicine use/total number of days with evaluable data X 100. A mixed model was used with treatment as a fixed effect with baseline number of puffs and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [15]
0
0
26 Weeks
Query!
Secondary outcome [16]
0
0
Standardized FEV1 (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours at Day 1 and Week 26
Query!
Assessment method [16]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, and 4 hours post-dose. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time. A mixed model was used with treatment as a fixed effect with baseline FEV1 and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [16]
0
0
From 5 minutes to 4 hours post-dose Day 1 and Week 26
Query!
Secondary outcome [17]
0
0
Standardized FEV1 (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 12 Hours at Day 1 and Week 26
Query!
Assessment method [17]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, 4, 8, 12 hours post-dose. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time. A mixed model was used with treatment as a fixed effect with baseline FEV1 and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [17]
0
0
From 5 minutes to 12 hours post-dose Day 1 and Week 26
Query!
Secondary outcome [18]
0
0
Standardized FEV1 (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 23 Hours 45 Minutes at Week 26
Query!
Assessment method [18]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, 4, 8, 12, 23 hours 15 minutes and 23 hours 45 minutes post-dose. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time. A mixed model was used with treatment as a fixed effect with baseline FEV1 and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.
Query!
Timepoint [18]
0
0
From 5 minutes to 23 hours 45 minutes post-dose Week 26
Query!
Secondary outcome [19]
0
0
24 Hour Holter Monitoring in a Subset of Patients
Query!
Assessment method [19]
0
0
24-hourly mean heart rate was performed using a Holter Monitor at Weeks 12 and 26 in a subgroup of patients. Mixed model: heart rate = treatment + baseline heart rate + baseline smoking status + baseline ICS use + region + center (region) + error. Center was included as a random effect nested within region.
The 24-hourly mean heart rate is the mean heart rate over the 24 hour period, derived using hourly mean heart rate beats per minute.
Query!
Timepoint [19]
0
0
Week 12, Week 26
Query!
Secondary outcome [20]
0
0
Rate of Moderate or Severe COPD Exacerbation
Query!
Assessment method [20]
0
0
Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years
Query!
Timepoint [20]
0
0
26 Weeks
Query!
Secondary outcome [21]
0
0
Percentage of Patients With at Least One Moderate or Severe COPD Exacerbation Over the 26 Week Treatment Period
Query!
Assessment method [21]
0
0
Query!
Timepoint [21]
0
0
26 Weeks
Query!
Secondary outcome [22]
0
0
Percentage of Participants With COPD Exacerbations Requiring Hospitalization or Treatment With Systemic Corticosteroids and/or Antibiotics But no Hospitalization
Query!
Assessment method [22]
0
0
Query!
Timepoint [22]
0
0
26 Weeks
Query!
Eligibility
Key inclusion criteria
- Male or female adults aged =40 yrs
- Smoking history of at least 10 pack years
- Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008)
- Post-bronchodilator FEV1 < 80% and = 30% of the predicted normal value and
post-bronchodilator FEV1/FVC (forced vital capacity) <70%
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1
- Patients with concomitant pulmonary disease
- Patients with a history of asthma
- Any patient with lung cancer or a history of lung cancer
- Patients with a history of certain cardiovascular co-morbid conditions
- Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency
- Patients in the active phase of a supervised pulmonary rehabilitation program
- Patients contraindicated for inhaled anticholinergic agents and ß2 agonists
- Other protocol-defined inclusion/exclusion criteria may apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
2144
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Daw Park
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Glebe
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - Kogarah
Query!
Recruitment hospital [4]
0
0
Novartis Investigative Site - Nedlands
Query!
Recruitment hospital [5]
0
0
Novartis Investigative site - New lambton
Query!
Recruitment postcode(s) [1]
0
0
- Daw Park
Query!
Recruitment postcode(s) [2]
0
0
- Glebe
Query!
Recruitment postcode(s) [3]
0
0
- Kogarah
Query!
Recruitment postcode(s) [4]
0
0
- Nedlands
Query!
Recruitment postcode(s) [5]
0
0
- New lambton
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Michigan
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Minnesota
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Missouri
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Nebraska
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Ohio
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Oregon
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
South Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Tennessee
Query!
Country [12]
0
0
Bulgaria
Query!
State/province [12]
0
0
Pleven
Query!
Country [13]
0
0
Bulgaria
Query!
State/province [13]
0
0
Russe
Query!
Country [14]
0
0
Bulgaria
Query!
State/province [14]
0
0
Sofia
Query!
Country [15]
0
0
Bulgaria
Query!
State/province [15]
0
0
Stara Zagora
Query!
Country [16]
0
0
Bulgaria
Query!
State/province [16]
0
0
Varna
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
British Columbia
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Ontario
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Quebec
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Beuvry
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Bourges
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Ferolles-Attily
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Rennes
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Berlin
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Erfurt
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Geesthacht
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Hanover
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Leipzig
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Minden
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Witten
Query!
Country [31]
0
0
Guatemala
Query!
State/province [31]
0
0
Guatemala City
Query!
Country [32]
0
0
Hungary
Query!
State/province [32]
0
0
Balassagyarmat
Query!
Country [33]
0
0
Hungary
Query!
State/province [33]
0
0
Budapest
Query!
Country [34]
0
0
Hungary
Query!
State/province [34]
0
0
Gyor
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Komarom
Query!
Country [36]
0
0
Hungary
Query!
State/province [36]
0
0
Nyiregyhaza
Query!
Country [37]
0
0
Hungary
Query!
State/province [37]
0
0
Tatabanya
Query!
Country [38]
0
0
Japan
Query!
State/province [38]
0
0
Asahikawa
Query!
Country [39]
0
0
Japan
Query!
State/province [39]
0
0
Chiba
Query!
Country [40]
0
0
Japan
Query!
State/province [40]
0
0
Chuo-ku
Query!
Country [41]
0
0
Japan
Query!
State/province [41]
0
0
Fukuoka
Query!
Country [42]
0
0
Japan
Query!
State/province [42]
0
0
Hachioji
Query!
Country [43]
0
0
Japan
Query!
State/province [43]
0
0
Hamakita
Query!
Country [44]
0
0
Japan
Query!
State/province [44]
0
0
Himeji
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Hiroshima
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Hitachi
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Itabashi
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Iwata
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Kamogawa
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Kishiwada
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Kiyose
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Kurashiki
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Matsusaka
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Matumoto
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Minato-ku
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Moriya
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Nagaoka
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Nagoya
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Niigata
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Obihiro
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Sakaide
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Sakai
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Sapporo
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Tachikawa
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Takatsuki
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Tsu
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Yabu
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Yanagawa
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Yatsushiro
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Yonezawa
Query!
Country [71]
0
0
Philippines
Query!
State/province [71]
0
0
Bulacan
Query!
Country [72]
0
0
Philippines
Query!
State/province [72]
0
0
Las Pinas City
Query!
Country [73]
0
0
Philippines
Query!
State/province [73]
0
0
Manila
Query!
Country [74]
0
0
Philippines
Query!
State/province [74]
0
0
Pasay City
Query!
Country [75]
0
0
Philippines
Query!
State/province [75]
0
0
Quezon City
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Krakow
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Proszowice
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Tarnov
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Warsaw
Query!
Country [80]
0
0
Russian Federation
Query!
State/province [80]
0
0
Barnaul
Query!
Country [81]
0
0
Russian Federation
Query!
State/province [81]
0
0
Kazan
Query!
Country [82]
0
0
Russian Federation
Query!
State/province [82]
0
0
Moscow
Query!
Country [83]
0
0
Russian Federation
Query!
State/province [83]
0
0
Nizhny Novgorod
Query!
Country [84]
0
0
Russian Federation
Query!
State/province [84]
0
0
Nizhny Novogorod
Query!
Country [85]
0
0
Russian Federation
Query!
State/province [85]
0
0
Samara
Query!
Country [86]
0
0
Russian Federation
Query!
State/province [86]
0
0
Saratov
Query!
Country [87]
0
0
Russian Federation
Query!
State/province [87]
0
0
St. Petersburg
Query!
Country [88]
0
0
Russian Federation
Query!
State/province [88]
0
0
Ufa
Query!
Country [89]
0
0
Slovakia
Query!
State/province [89]
0
0
Bardejov
Query!
Country [90]
0
0
Slovakia
Query!
State/province [90]
0
0
Bojnice
Query!
Country [91]
0
0
Slovakia
Query!
State/province [91]
0
0
Bratislava
Query!
Country [92]
0
0
Slovakia
Query!
State/province [92]
0
0
Humenne
Query!
Country [93]
0
0
Slovakia
Query!
State/province [93]
0
0
Kosice
Query!
Country [94]
0
0
Slovakia
Query!
State/province [94]
0
0
Liptovsky Hradok
Query!
Country [95]
0
0
Slovakia
Query!
State/province [95]
0
0
Partizanske
Query!
Country [96]
0
0
Slovakia
Query!
State/province [96]
0
0
Prievidza
Query!
Country [97]
0
0
Slovakia
Query!
State/province [97]
0
0
Spisska Nova Ves
Query!
Country [98]
0
0
Slovakia
Query!
State/province [98]
0
0
Trstena
Query!
Country [99]
0
0
Slovakia
Query!
State/province [99]
0
0
Zilina
Query!
Country [100]
0
0
Slovakia
Query!
State/province [100]
0
0
Zvolen
Query!
Country [101]
0
0
South Africa
Query!
State/province [101]
0
0
Cape Town
Query!
Country [102]
0
0
South Africa
Query!
State/province [102]
0
0
Durban
Query!
Country [103]
0
0
South Africa
Query!
State/province [103]
0
0
Johannesburg
Query!
Country [104]
0
0
South Africa
Query!
State/province [104]
0
0
Lyttleton
Query!
Country [105]
0
0
South Africa
Query!
State/province [105]
0
0
Pretoria
Query!
Country [106]
0
0
Spain
Query!
State/province [106]
0
0
Alcira
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Badalona
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Barcelona
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Canet de Mar
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Centelles
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Ferrol
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Fuenlabrada
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Les Borges del Camp
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Madrid
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Mataro
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Merida
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Mostoles
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Motril
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
Palma de Mallorca
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Ponferrada
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Salamanca
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Salt
Query!
Country [123]
0
0
Spain
Query!
State/province [123]
0
0
Valencia
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Vic
Query!
Country [125]
0
0
Switzerland
Query!
State/province [125]
0
0
Basel
Query!
Country [126]
0
0
Switzerland
Query!
State/province [126]
0
0
Lugano
Query!
Country [127]
0
0
Switzerland
Query!
State/province [127]
0
0
Munchenstein
Query!
Country [128]
0
0
Switzerland
Query!
State/province [128]
0
0
Neuchatel
Query!
Country [129]
0
0
Switzerland
Query!
State/province [129]
0
0
Zurich
Query!
Country [130]
0
0
Taiwan
Query!
State/province [130]
0
0
Chai-Yi
Query!
Country [131]
0
0
Taiwan
Query!
State/province [131]
0
0
Kaohsiung
Query!
Country [132]
0
0
Taiwan
Query!
State/province [132]
0
0
Taichung
Query!
Country [133]
0
0
Taiwan
Query!
State/province [133]
0
0
Taipei
Query!
Country [134]
0
0
Turkey
Query!
State/province [134]
0
0
Adana
Query!
Country [135]
0
0
Turkey
Query!
State/province [135]
0
0
Ankara
Query!
Country [136]
0
0
Turkey
Query!
State/province [136]
0
0
Bolu
Query!
Country [137]
0
0
Turkey
Query!
State/province [137]
0
0
Bursa
Query!
Country [138]
0
0
Turkey
Query!
State/province [138]
0
0
Canakkale
Query!
Country [139]
0
0
Turkey
Query!
State/province [139]
0
0
Denizli
Query!
Country [140]
0
0
Turkey
Query!
State/province [140]
0
0
Istanbul
Query!
Country [141]
0
0
Turkey
Query!
State/province [141]
0
0
Izmir
Query!
Country [142]
0
0
Turkey
Query!
State/province [142]
0
0
Kocaeli
Query!
Country [143]
0
0
Turkey
Query!
State/province [143]
0
0
Manisa
Query!
Country [144]
0
0
Turkey
Query!
State/province [144]
0
0
Mersin
Query!
Country [145]
0
0
United Kingdom
Query!
State/province [145]
0
0
Bath
Query!
Country [146]
0
0
United Kingdom
Query!
State/province [146]
0
0
Blackpool
Query!
Country [147]
0
0
United Kingdom
Query!
State/province [147]
0
0
Bradford
Query!
Country [148]
0
0
United Kingdom
Query!
State/province [148]
0
0
Cambs
Query!
Country [149]
0
0
United Kingdom
Query!
State/province [149]
0
0
Chelmsford
Query!
Country [150]
0
0
United Kingdom
Query!
State/province [150]
0
0
Chesterfield
Query!
Country [151]
0
0
United Kingdom
Query!
State/province [151]
0
0
Glasgow
Query!
Country [152]
0
0
United Kingdom
Query!
State/province [152]
0
0
Herts
Query!
Country [153]
0
0
United Kingdom
Query!
State/province [153]
0
0
Isle of Wight
Query!
Country [154]
0
0
United Kingdom
Query!
State/province [154]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to provide pivotal efficacy and safety data for QVA149 in
patients with moderate to severe COPD.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01202188
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01202188
Download to PDF